Product Description
Methyltestosterone is a methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Methyltestosterone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Brazil | Canada | Chile | Hong Kong | India | Ireland | New Zealand | Pakistan | Peru | Russia | Taiwan | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/03/2026 |
News Article |
SoFi and Mastercard Partner to Enable SoFiUSD Settlement Across Mastercard's Global Payments Network |
|
03/03/2026 |
News Article |
MasterClass Launches AI and Medicine to Help Members Navigate Modern Healthcare |
|
03/03/2026 |
News Article |
EliseAI Launches Agent by EliseAI, a Mobile App for Today's AI-Powered Leasing Environment |
|
03/03/2026 |
News Article |
Shake Shack to Participate in Upcoming March Investor Conferences |